|Videos|April 22, 2019

Why Are Alternative Options for Treating Chronic Bone and Joint Infections Needed?

Tristan Ferry, MD, PhD, discusses why there is a need to develop alternatives to treat chronic bone and joint infections.

Segment Description: Tristan Ferry, MD, PhD, co-head of the Infectious Diseases Unit at Lyon University Hospital in France, discusses why there is a need to develop alternatives to treat chronic bone and joint infections.

Interview transcript (modified slightly for readability):

Contagion®: Your talk covered alternative options to managing chronic bone and joint infections. Why are the alternative options needed?

Dr. Ferry: Patients with chronic bone and joint infections are very difficult to treat because they are infected with persisters bacteria and it's very difficult to eradicate. Most patients require surgery that could be associated with a loss of function such as explantation. It's very important to imagine the different options to limit the consequence of invasive surgery with some antibiotics or anti-persisters that could act on the bacteria to cure the patient.

The symposium, "Alternative options to rescue patients: novel anti-persister antibiotics, local antibiotic delivery, phage therapy," was presented Saturday, April 13, at ECCMID 2019.


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.